Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations:

Sahebkar, A and Serban, M-C and Penson, P and Gurban, C and Ursoniu, S and Toth, P and Jones, S and Lippi, G and Kotani, K and Kostner, K and Rizzo, M and Rysz, J and Banach, M The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations:. Drugs. ISSN 0012-6667 (Accepted)

[img] Text
Tamoxifen DRUGS_final.pdf - Accepted Version
Restricted to Repository staff only

Download (251kB)

Abstract

Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with reduced circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less-well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) (Lp(a)) through systematic review and meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, Medline and EMBASE were searched from inception until 22nd March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Results: Meta-analysis of 5 studies with 284 participants suggested a significant reduction of Lp(a) levels following tamoxifen treatment (weighted mean difference [WMD]: -3.53 mg/dL, 95% confidence interval [CI]: -6.53, -0.53, p=0.021). When studies were categorized according tamoxifen dose, there was a significant effect in the subset of studies with administered doses ≥20 mg/day (WMD: -5.05 mg/dL, 95% CI: -7.86, -2.23, p<0.001), but not in the subset with doses <20 mg/day (WMD: -1.41 mg/dL, 95% CI: -5.13, 2.31, p=0.458). With respect to duration of treatment, a greater effect was observed in subgroup of studies administering tamoxifen for <12 weeks (WMD: -4.01 mg/dL, 95% CI: -7.84, -0.18, p=0.04) versus the subgroup of studies lasting ≥12 weeks (WMD: -2.48 mg/dL, 95% CI: -5.50, 0.53, p=0.107). Conclusions: Meta-analysis suggested a significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.

Item Type: Article
Uncontrolled Keywords: 1115 Pharmacology And Pharmaceutical Sciences
Subjects: Q Science > QD Chemistry
R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Springer Verlag Adis
Date Deposited: 16 May 2017 11:16
Last Modified: 16 May 2017 11:16
URI: http://researchonline.ljmu.ac.uk/id/eprint/6432

Actions (login required)

View Item View Item